CollPlant Biotechnologies Ltd. (CLGN)

NASDAQ: CLGN · IEX Real-Time Price · USD
5.65
-0.02 (-0.35%)
At close: Feb 26, 2024, 4:00 PM
5.67
+0.02 (0.35%)
After-hours: Feb 26, 2024, 4:00 PM EST
-0.35%
Market Cap 64.71M
Revenue (ttm) 10.72M
Net Income (ttm) -6.73M
Shares Out 11.45M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE 4.92
Dividend n/a
Ex-Dividend Date n/a
Volume 2,807
Open 5.67
Previous Close 5.67
Day's Range 5.35 - 5.67
52-Week Range 4.70 - 11.50
Beta 0.41
Analysts Strong Buy
Price Target 11.00 (+94.69%)
Earnings Date Mar 27, 2024

About CLGN

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration o... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 73
Stock Exchange NASDAQ
Ticker Symbol CLGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for CLGN stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target
$11.0
(94.69% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

CollPlant Issues Letter to Shareholders

REHOVOT, Israel , Feb. 15, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its n...

12 days ago - PRNewsWire

CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California

REHOVOT, Israel , Jan. 8, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its no...

7 weeks ago - PRNewsWire

CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants

The current market for breast implants is estimated at $2.6 billion a year CollPlant expects the study to conclude by the first half of 2024 CollPlant plans to use findings from this study and success...

2 months ago - PRNewsWire

CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023

Received a $10 million milestone payment in the third quarter from partner, AbbVie Inc., for achieving a major milestone in the second quarter in accordance with the strategic collaboration agreement ...

3 months ago - PRNewsWire

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

-  Conference call to be held on Wednesday, November 29, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , Nov. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesth...

3 months ago - PRNewsWire

CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler

-  Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Potential Products - REHOVOT, Israel , Nov. 1, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN...

4 months ago - PRNewsWire

CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative

- As a new participant, the Company strengthens its commitment to operate sustainably and transition the regenerative and aesthetics medicine industry to sustainable alternatives - REHOVOT, Israel , S...

5 months ago - PRNewsWire

CollPlant to Present at the H.C. Wainwright Annual Growth Conference

REHOVOT, Israel , Sept. 5, 2023 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its no...

6 months ago - PRNewsWire

CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million

Received in July 2023, $10 million from partner, AbbVie, for achieving a major milestone in the second quarter, for the clinical-phase dermal filler product in accordance with the strategic collaborat...

6 months ago - PRNewsWire

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

-  Conference call to be held on Thursday, August 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel, Aug. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic...

7 months ago - PRNewsWire

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

-  Conference call to be held on Thursday, August 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , Aug. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aestheti...

7 months ago - PRNewsWire

CollPlant Achieves Milestone and To Receive $10 Million From AbbVie in Accordance with its Regenerative Dermal Filler Product Collaboration Agreement

REHOVOT, Israel , June 26, 2023 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its no...

8 months ago - PRNewsWire

CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update

Strong positive sales trajectory for rhCollagen based products Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant's recombin...

9 months ago - PRNewsWire

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

-  Conference call to be held on May 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , May 2, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine co...

10 months ago - PRNewsWire

Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs

EDEN PRAIRIE, Minn. & REHOVOT, Israel--(BUSINESS WIRE)---- $SSYS #3dprinting--Stratasys Ltd. (Nasdaq: SSYS) and CollPlant Biotechnologies (Nasdaq: CLGN) today announced a joint development and commerc...

Other symbols: SSYS
11 months ago - Business Wire

Collplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update

Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant's recombinant human (rh)Collagen Additional large-animal study planned in...

11 months ago - PRNewsWire

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

- Conference call to be held on March 29, 2023 at 10:00 am U.S. EDT - REHOVOT, Israel , March 14, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine...

1 year ago - PRNewsWire

CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives

Study demonstrated progressive stages of tissue regeneration as highlighted by the formation of maturing connective tissue and neovascular networks within the implants No indication of adverse reactio...

1 year ago - PRNewsWire

CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form

Company's first bioink available in powder form provides enhanced operational flexibility to support a wide range of 3D bioprinting applications Collink.3D™ 50L strengthens CollPlant's platform of bio...

1 year ago - PRNewsWire

CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results

Partnership with AbbVie to co-develop rhCollagen-based dermal and soft tissue fillers continues to advance according to plan Co-developing 3D bioprinted human intestine model ("Gut-on-a-Chip") for dru...

1 year ago - PRNewsWire

CollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis

Agreement to accelerate development of a 'Gut-on-a-Chip' tissue model to improve therapeutic choice and outcome of ulcerative colitis patients CollPlant to fund development and receive exclusive licen...

1 year ago - PRNewsWire

CollPlant Expands rhCollagen-Based Bioink Platform with Launch of Collink.3D™ 90

Collink.3D™ 90 offers additional functionality to address wide range of 3D bioprinting applications, including soft and hard tissues Collink.3D™ 90 demonstrates faster human cell migration into gel ma...

1 year ago - PRNewsWire

CollPlant to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17

REHOVOT, Israel , Nov. 3, 2022 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative human-collagen based technologies and prod...

1 year ago - PRNewsWire

CollPlant to present at the Dawson James Small Cap Growth Conference on October 12

REHOVOT, Israel , Oct. 3, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regen...

1 year ago - PRNewsWire

CollPlant to Present at the International Conference on Biofabrication 2022 in Tuscany, Italy

REHOVOT, Israel , Sept. 19, 2022 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissu...

1 year ago - PRNewsWire